An observational study in Epilepsy, sponsored by Fondation Ophtalmologique Adolphe de Rothschild. Terminated at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by Fondation Ophtalmologique Adolphe de Rothschild · Observational
Insufficient enrollement of patients
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Epilepsy by Fondation Ophtalmologique Adolphe de Rothschild — 7 open to participants now, 7 under way, none of them phase 3. Epilepsy · Fondation Ophtalmologique Adolphe de Rothschild.
Among the 10 studies in Epilepsy by Fondation Ophtalmologique Adolphe de Rothschild, this one is the only one that started in 2024, is one of 7 observational ones, and was the 6th registered.
1,850 studies on the registry are indexed under Epilepsy; 418 are open to participants now.
Browse Epilepsy studies →7 of the 10 studies in Epilepsy by Fondation Ophtalmologique Adolphe de Rothschild are open now, in 1 country. Recruiting first, the newest first:
Fondation Ophtalmologique Adolphe de Rothschild · Sites in France
Ages 18+
Fondation Ophtalmologique Adolphe de Rothschild · Sites in France
Fondation Ophtalmologique Adolphe de Rothschild · Sites in France
Ages 18–65 · Healthy volunteers
Fondation Ophtalmologique Adolphe de Rothschild · Sites in France
Ages 18+
Fondation Ophtalmologique Adolphe de Rothschild · Sites in France
Ages 6–18
By country, each count listing its studies:
Of the 284 Epilepsy studies recruiting now, 113 (40%) set no upper age limit and 148 (52%) stop at 75 or younger; 138 take children under 18; 54 take healthy volunteers.
This study: 18 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 1 started in 2024.
This study's enrollment of 45 is below the median of 107 across 541 observational studies indexed under Epilepsy.
Median enrollment 76 across the 3 interventional studies, 50 across the 7 observational. Of the 3 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Fondation Ophtalmologique Adolphe de Rothschild is the lead sponsor of 316 studies on the registry; 78 are open to participants now.
3 of the studies in Epilepsy by Fondation Ophtalmologique Adolphe de Rothschild that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07075380Fondation Ophtalmologique Adolphe de RothschildNational Survey on Physical and Sports Activity of Adults With Epilepsy | 2027-05 |
| NCT04451278Fondation Ophtalmologique Adolphe de RothschildRESting-state Functional MRI for Prediction of Post-surgical Prognosis In Pediatric Drug-Resistant Epilepsy | 2027-10 |
| NCT07026591Fondation Ophtalmologique Adolphe de RothschildEpilepsy and Driving | 2027-11 |
Add all 3 to your calendar (.ics) → With an account.
Among the 10 studies in Epilepsy by Fondation Ophtalmologique Adolphe de Rothschild, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The unpredictable nature of epileptic seizures places people with epilepsy under permanent psychological stress, which contributes significantly to a restriction in their quality of life. The possibility of predicting the arrival of epileptic seizures would allow, in addition to taking a preventive treatment if the risk of seizure is close, to prevent traumas and accidents linked to possible falls during seizures, to authorize driving for certain people with epilepsy and to reduce the costs of medical care. To date and to our knowledge, no seizure detection device has been commercialized. There are commercialized devices based on biometric sensors other than EEG, but these are strictly dedicated to the detection of seizures and do not allow the anticipation of seizures. Regarding prediction, current research seems to have difficulties in developing convincing algorithms. The only system used successfully in real time would require a device implantable in the brain, but this would raise problems of acceptability.
In addition, 20% of people with drug-resistant epilepsy have psychogenic non-epileptic seizures (PNES). These are sometimes difficult to differentiate from epileptic seizures by people with epilepsy and their caregivers, and their management differs from that of epileptic seizures. The distinction between these 2 types of events should also be taken into account by these prediction/detection tools.
From the field of biomedical detection dogs, there is currently a converging body of evidence supporting that people with epilepsy emit specific odors associated with seizure events. Trained dogs have been shown to be able to discriminate body odors sampled during or just after an epileptic seizure from those sampled from the same subjects in various contexts outside of a seizure. It was also shown that a seizure can also be predicted by the volatile organic compounds (VOCs) released by the patient (human volatilome); the olfactory signature being already detectable up to 3h before a seizure. Another study used trained dogs to confirm that they are able to detect a seizure by smell and that this olfactory difference is already detectable before a seizure.
The human volatilome VOCs lead is particularly promising, notably for its non-invasiveness and for the pre-ictal precocity that prediction allows. But at the moment, the studies are too studies are too preliminary, with sample sizes too small to conclude on the inter-individual generalization of the odor, taking into account the type of seizure involved and the influence of other variables (e.g., gender, age, medications). Moreover, in order to develop a reliable and transportable electronic detection tool, the identification of the VOCs involved is necessary, since the choice of sensors (e.g., to constitute an electronic nose) depends on it. The objective of this study is to overcome these shortcomings, by aiming at the identification of the informative odor(s) associated with epileptic events during the pre-ictal, ictal and post-ictal periods, taking into account the type of seizures (focal seizures, secondary generalized focal seizures, primary generalized seizures - motor and non-motor) and the inter-individual differences.
The epileptics will be recruited by the neurologists from among the epileptics treated at the Institut la Teppe and the Fondation A de Rothschild Hospital who meet the selection criteria.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Focal seizures Focal seizures with secondary generalization Generalized seizures - motor or non-motor
Exclusion Criteria:
* Continuous systematic sampling at HFAR: Samples every 3 hours (3 a.m., 6 a.m., 9 a.m., 12 p.m., 3 p.m., 6 p.m., 9 p.m., midnight) until the end of the monitoring period. * Systematic sampling during the day: Samples every 3 hours at Institut La TEPPE (9am, 12pm, 3pm, 6pm, 9pm) until the end of the follow-up period. * Sampling in case of epileptic seizure : Sampling during the seizure (from t0 to t+5 min), whatever the time. The samples will be taken using a compress on the forehead, the palms of the hands and the back of the neck. The compress will then be placed in a freezer bag and the person with epilepsy will be asked to exhale into the bag, if he/she is able to do so, before closing it.
Identification of human volatile organic compounds (VOCs) biopredictors of epileptic seizures.
Distribution of molecules or pieces of molecules per sample.
Time frame: Day 0
Ran from Feb 2024 to primary completion in May 2026, 27 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 7, 2026: primary completion Jun 2026 → May 2026 and completion Jun 2026 → May 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
Insufficient enrollement of patients
Insufficient enrollement of patients
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fondation Ophtalmologique Adolphe de Rothschild →